Moderna stock outlook rises after profit return and stronger sales

Moderna returned to quarterly profitability and raised its full-year sales outlook in results released on Friday, November 6, 2026. CNBC reported that the biotechnology company exceeded Wall Street expectations as newer products gained traction and international COVID vaccine sales strengthened.

Moderna stock traded at 231.28 euros on Lang & Schwarz at 14:04 CET on Monday, November 9; the real-time quote of Moderna stock is available here.

Revenue growth broadens beyond COVID

Third-quarter revenue increased 29 percent to 1.31 billion US dollars, according to CNBC. International markets contributed 533 million US dollars, while the United States generated 780 million US dollars. The company attributed the increase mainly to higher COVID vaccine sales abroad and deliveries under long-term government partnerships.

The result also reflected progress in Moderna's broader commercial portfolio. Chief Executive Officer Stephane Bancel said newer product launches and geographic diversification supported the quarter. He pointed to the full-year contribution from the next-generation mRNA COVID vaccine, which received US approval in May 2025, while the stand-alone flu vaccine approved in August is still in an early US launch phase.

Profitability improves as costs fall

Moderna reported net income of 162 million US dollars, compared with a net loss of 200 million US dollars in the third quarter of 2025. Diluted earnings per share came to 38 cents, versus a loss of 51 cents a year earlier. The figures exceeded the expectations cited by CNBC, which were a loss of 1.25 US dollars per share and revenue of 885.1 million US dollars.

Management linked the earnings improvement to stronger sales and lower costs. The company is also advancing its oncology pipeline after positive late-stage data for its personalized cancer vaccine with Merck in melanoma. The program remains an important longer-term driver, although commercial execution and regulatory progress are still required before it can materially diversify revenue.

Higher outlook raises execution stakes

Moderna now expects 2026 revenue growth of 15 percent to 25 percent, compared with its previous outlook for growth of up to 10 percent. The revised range reflects stronger vaccine demand, product launches and a wider geographic footprint. For investors, the forecast increases the importance of fourth-quarter deliveries and the pace at which newer products contribute to sales.

The improved quarter supports the case that Moderna's cost reduction program can cushion seasonal swings in vaccine demand. At the same time, the business remains exposed to the timing of vaccination campaigns, government supply agreements and the development path of its oncology candidates. Those factors will shape whether the raised outlook becomes a durable improvement rather than a single strong quarter.

Broader market context is available in current S&P 500 reports.

For more company-specific coverage, see more news and analyses on Moderna stock.